Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi Builds Blood Disorder Specialty With Bioverativ Buy

Executive Summary

The French drug maker is making a big splash into blood disorders with the $11.6bn acquisition of hemophilia specialist Bioverativ. Eloctate and Alprolix are young and growing brands, but the competition in hemophilia is fierce, which means Bioverativ's pipeline will also need to deliver to justify the premium price.


Related Content

Why The M&A Boom Many Expected In 2018 Didn’t Happen
Why The M&A Boom Many Expected In 2018 Didn’t Happen
Bayer's Hemophilia A Portfolio Boosted by Jivi's EU Approval
Bioverativ: More Than Just A Hemophilia Company
Deal Watch: As J.P. Morgan Waits For New Deals, Sanofi Takes Care Of Old Business
Spark Plots Rebound For Hemophilia A Gene Therapy, As Rival BioMarin Surges
Non-Inhibitor Data Secure Roche's Competitive Position In Hemophilia A
Bioverativ Fills Gap In Pipeline With $400m True North Buy
Pressed Sanofi CEO Hopes For Positive Dupixent Launch, Praluent Ruling
Bioverativ Hits The Street Ready To Expand In Blood Disorders


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts